{'fraction_non_alphanumeric': 0.0495703899537343, 'fraction_numerical': 0.0449438202247191, 'mean_word_length': 4.823076923076923, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
4CPS-207 Screening for painful diabetic neuropathy

Background Neurological complications are common in diabetes and mainly result in peripheral neuropathy. Purpose The aim of this study was to detect PDN in a diabetic population and describe the factors associated with this complication. Material and methods This is a descriptive and analytical study of a total of 90 diabetic patients who were hospitalised or consulted between June and August 2018 in the endocrinology department of our hospital. For screening we used the DN4 questionnaire. This questionnaire is divided into four questions representing 10 items to check. For each patient we counted a score. If the score was greater than or equal to 4/10, the test was positive. For patient information we used a pre-established record card. Results The study population had a mean age of 54.3±15.35 years, a sex ratio (M/F) of 0.84 and was predominantly composed of type-2 diabetics (88%). Thirty patients screened positive on the DN4 (≥4/10). PDN was not associated with age (p=0.412), sex (p=0.549) or type of diabetes (p=0.111). It was associated with high blood pressure (p=0.007), insulin (p=0.003) and metformin (p=0.022). Conclusion The DN4 questionnaire is a simple tool that facilitates the recognition of painful diabetic neuropathy, which is a frequent and sometimes disabling complication of diabetes. References and/or acknowledgements http://www.eahp.eu/sites/default/files/files/ejhpharm-2013–000276_Single_PDF.pdf No conflict of interest.